De novo Prediction of Cell-Drug Sensitivities Using Deep Learning-based Graph Regularized Matrix Factorization

Area of Science:

• Computational biology
• Artificial intelligence in oncology
• Drug discovery and repurposing

Background:

• Precision oncology leverages AI to predict patient cancer cell response to existing anticancer drugs.
• AI can also repurpose drugs for novel anticancer applications by predicting their efficacy on new cancer cell types.
• Existing methods often address these tasks separately, limiting comprehensive drug response prediction.

Purpose of the Study:

• To develop a unified artificial intelligence (AI) framework, DeepGRMF, for predicting anticancer drug efficacy.
• To integrate diverse data sources including drug chemical structures, cellular signaling pathways, and cancer cell states.
• To enhance drug response prediction for both known and novel anticancer agents in precision oncology.

Main Methods:

• Developed DeepGRMF, a computational model integrating neural networks, graph models, and matrix factorization.
• The model learns embeddings for drugs and cells, capturing similarities in chemical structure, mechanism of action, and cellular states.
• Utilized Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) datasets for model training and evaluation.

Main Results:

• DeepGRMF demonstrated superior prediction performance compared to existing models on GDSC and CCLE datasets.
• The model successfully learned meaningful representations of drugs and cells in an embedding space.
• Validated the model's capability to predict chemotherapy regimen effectiveness on lung cancer patient outcomes using The Cancer Genome Atlas (TCGA) data.

Conclusions:

• DeepGRMF provides a unified AI framework for predicting drug response in precision oncology.
• The model's ability to integrate diverse biological and chemical data enhances prediction accuracy for known and novel drugs.
• This approach holds promise for accelerating drug discovery, repurposing, and personalizing cancer treatment strategies.